ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Trial status:Recruitment Complete
Trial ID:
PRESERVE-004
NCT ID:
NCT05446298
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
OncoC4, Inc.
Recruitment Complete

Trial Details

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

Medical Condition
  • Ovarian Cancer
    • Trial Drug
  • ONC-392
    • See more
  • Pembrolizumab
    • Phase
    Phase 2
    Type
    Interventional
    Estimated Enrolment
    58
    Estimated Trial Date
    Dec 2022 - Jun 2025

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Cancer Treatment Centers of America, Phoenix. 403
    Goodyear, Arizona, United States, 85338
    Status
    Location
    Honor Health, USOR, 406
    Phoenix, Arizona, United States, 85082
    Status
    Location
    Nuvance Health System, 401
    Danbury, Connecticut, United States, 06856
    Status
    Location
    Baptist MD Anderson Cancer Center, 404
    Jacksonville, Florida, United States, 32207
    Status
    Location
    Sudarshan Sharma, MD. LTD. 414
    Hinsdale, Illinois, United States, 60521
    Status
    Location
    Cancer Treatment Centers of America, Chicago. 410
    Zion, Illinois, United States, 60099
    Status